1-5 of 5
Celeste Richardson
Close
Sort by
Journal Articles

Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies

Eugene Choi, Jae-Woong Chang, Joshua Krueger, Walker S Lahr, Emily Pomeroy, Meghan Walsh, Annie Khamhoung, Jennifer Johnson, Charlotte Franco, Lukasz Swiech, Simarjot Pabla, Celeste Richardson, Vipin Suri, Beau R Webber, Branden S Moriarity
Journal: Blood
Blood (2021) 138 (Supplement 1): 1691.
https://doi.org/10.1182/blood-2021-148649
Published: 2021
Journal Articles

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, Alfred L. Garfall, MD, Edward A. Stadtmauer, MD FACP, Simon F Lacey, PhD BS, Eric Lancaster, Dan T. Vogl, MD, Brendan M Weiss, MD, David E Ambrose, BS, Anne Marie Nelson, Fang Chen, PhD, Gabriela Plesa, MD, Irina Kulikovskaya, Vanessa Gonzalez, Minnal Gupta, Regina M Young, PhD, Karen Dengel, BSN, RN, Laura O'keefe, Samantha Le, Celeste Richardson, PhD, Randi E. Isaacs, MD, J. Joseph Melenhorst, PhD, Bruce L Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 505.
https://doi.org/10.1182/blood.V130.Suppl_1.505.505
Published: 2017
Journal Articles

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

Alfred L. Garfall, MD, Eric Lancaster, MD PhD, Edward A Stadtmauer, MD, Simon F. Lacey, PhD, Karen Dengel, BSN, RN, David E Ambrose, BS, Fang Chen, PhD, Minnal Gupta, MSc, Irina Kulikovskaya, PhD, Dan T. Vogl, MD, Gabriela Plesa, PhD, Brendan M Weiss, MD, Regina Ferthio, Celeste Richardson, PhD, Jan Joseph Melenhorst, PhD, Bruce L Levine, PhD, Carl H June, MD, Michael Milone, MD PhD, Adam D. Cohen, MD
Journal: Blood
Blood (2016) 128 (22): 5702.
https://doi.org/10.1182/blood.V128.22.5702.5702
Published: 2016
Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Adam D. Cohen, MD, Alfred L. Garfall, MD, Edward A Stadtmauer, MD, Simon Francis Lacey, PhD BS, Eric Lancaster, MD PhD, Dan T. Vogl, MD, Karen Dengel, BSN, RN, David E Ambrose, BS, Fang Chen, PhD, Gabriela Plesa, PhD, Irina Kulikovskaya, PhD, Vanessa E Gonzalez, M.B.A, Minnal Gupta, MSc, Regina M Young, PhD, Tenesia Carey, Regina Ferthio, Brendan M. Weiss, MD, Celeste Richardson, PhD, Randi E. Isaacs, MD, J. Joseph Melenhorst, PhD, Bruce L. Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1147.
https://doi.org/10.1182/blood.V128.22.1147.1147
Published: 2016
Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 766.
https://doi.org/10.1182/blood.V128.22.766.766
Published: 2016